At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
Vertex wins FDA approval for long-awaited non-opioid painkiller
Vertex Pharmaceuticals Inc. hit a major milestone on Thursday when the U.S. Food and Drug Administration approved its ...
Buy Rating for Vertex Pharmaceuticals: FDA Approval of Journavx Boosts Market Potential and Stock Price Target
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...
Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’
We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...
FDA approves first new class of painkiller in 20 years, a non-addictive opioid alternative
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
BioSpace4d
Cystic Fibrosis Biotech Sionna Announces $150M IPO
The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Bank of America Securities
In a report released today, Tazeen Ahmad from Bank of America Securities maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research ...